Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Konstantinos Papamichail, Ph.D., M.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
National and Kapodistrian University of Athens, School of Health Sciences, Medical School , Greece MD07/1999
National and Kapodistrian University of Athens, School of Health Sciences, Medical School, GreecePhD07/2007
2010
Poster Special Commendation
2011
Top Poster
2011
Poster of Distinction
2014
2nd Poster Prize
2014
ECCO Fellowship
2015
Poster of Distinction
2015
1st Poster Prize
2016
Poster of Distinction
2017
E-Poster oral presentation
2019
Oral presentation
2019
Top Digital Oral Presentation

Overview

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rakowsky S, Cheifetz AS, Papamichael K. Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease. Aliment Pharmacol Ther. 2021 10; 54(8):1085-1086. PMID: 34564884.
    Citations:    Fields:    Translation:Humans
  2. Cheifetz AS, Abreu MT, Afif W, Cross RK, Dubinsky MC, Loftus EV, Osterman MT, Saroufim A, Siegel CA, Yarur AJ, Melmed GY, Papamichael K. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. Am J Gastroenterol. 2021 10 01; 116(10):2014-2025. PMID: 34388143.
    Citations:    Fields:    
  3. Papamichael K, Dubinsky MC, Cheifetz AS. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases. JAMA. 2021 09 21; 326(11):1067. PMID: 34546306.
    Citations:    Fields:    Translation:Humans
  4. Alonso CD, Papamichael K, Sprague R, Barrett C, Gonzales-Luna AJ, Daugherty K, Garey KW, Villafuerte-Gálvez J, Xu H, Lin Q, Wang L, Chen X, Pollock NR, Kelly CP. Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection. Open Forum Infect Dis. 2021 Jul; 8(7):ofab286. PMID: 34258317.
    Citations:    
  5. Papamichael K, Vande Casteele N, Jeyarajah J, Jairath V, Osterman MT, Cheifetz AS. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021 05 01; 116(5):1007-1014. PMID: 33929379.
    Citations:    Fields:    Translation:Humans
  6. Llanos-Chea A, Shapiro JM, Winter RW, Jerger L, Menz T, Gibson M, Friedmann AM, Treaba D, Papamichael K, Cheifetz AS, Friedman S, Hamilton MJ, Winter HS. Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Dig Dis Sci. 2021 Feb 17. PMID: 33595782.
    Citations:    Fields:    
  7. Vande Casteele N, Abreu MT, Flier S, Papamichael K, Rieder F, Silverberg MS, Khanna R, Okada L, Yang L, Jain A, Cheifetz AS. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. Clin Gastroenterol Hepatol. 2021 Jan 06. PMID: 33421628.
    Citations:    Fields:    
  8. Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021 04; 19(4):854-855. PMID: 33248082.
    Citations:    Fields:    Translation:Humans
  9. Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, Gheysens K, Papamichael K, Osterman MT, Cheifetz AS, Cross RK. Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. J Clin Med. 2020 Sep 28; 9(10). PMID: 32998473.
    Citations: 1     
  10. White NC, Mendo-Lopez R, Papamichael K, Cuddemi CA, Barrett C, Daugherty K, Pollock N, Kelly CP, Alonso CD. Laxative Use Does Not Preclude Diagnosis or Reduce Disease Severity in Clostridiodes difficile Infection. Clin Infect Dis. 2020 09 12; 71(6):1472-1478. PMID: 31584632.
    Citations: 3     Fields:    Translation:Humans
  11. Papamichael K, Thomas VJ, Banty A, Clarke WT, Germansky KA, Flier SN, Feuerstein JD, Melmed GY, Cheifetz AS. Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay. J Clin Med. 2020 Sep 02; 9(9). PMID: 32887317.
    Citations:    
  12. Papamichael K, Cheifetz AS. Proactive Adalimumab Monitoring in Inflammatory Bowel Disease: Current Data and Future Perspectives. J Crohns Colitis. 2020 07 09; 14(6):878-879. PMID: 31761938.
    Citations:    Fields:    Translation:Humans
  13. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol. 2020 07; 32(4):371-379. PMID: 32412995.
    Citations: 1     Fields:    Translation:Humans
  14. Grossberg LB, Farraye FA, Papamichael K, Cheifetz AS, Feuerstein JD. A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. Inflamm Bowel Dis. 2020 06 18; 26(7):e59-e61. PMID: 32304571.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  15. Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis. 2020 May 21; 14(4):542-556. PMID: 31549158.
    Citations: 4     Fields:    Translation:Humans
  16. Papamichael K, Clarke WT, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 04; 19(4):839-841.e2. PMID: 32147594.
    Citations: 2     Fields:    Translation:Humans
  17. Papamichael K, Cheifetz AS, Irving PM. New role for azathioprine in case of switching anti-TNFs in IBD. Gut. 2020 07; 69(7):1165-1167. PMID: 32075889.
    Citations: 2     Fields:    Translation:Humans
  18. Negoescu DM, Enns EA, Swanhorst B, Baumgartner B, Campbell JP, Osterman MT, Papamichael K, Cheifetz AS, Vaughn BP. Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflamm Bowel Dis. 2020 01 01; 26(1):103-111. PMID: 31184366.
    Citations: 3     Fields:    Translation:Humans
  19. Fine S, Papamichael K, Cheifetz AS. Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2019 Dec; 15(12):656-665. PMID: 31892912.
    Citations: 9     
  20. Grossberg LB, Papamichael K, Leffler DA, Sawhney MS, Feuerstein JD. Patients over Age 75 Are at Increased Risk of Emergency Department Visit and Hospitalization Following Colonoscopy. Dig Dis Sci. 2020 07; 65(7):1964-1970. PMID: 31784850.
    Citations:    Fields:    Translation:Humans
  21. Clarke WT, Papamichael K, Vande Casteele N, Germansky KA, Feuerstein JD, Melmed GY, Siegel CA, Irving PM, Cheifetz AS. Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflamm Bowel Dis. 2019 10 18; 25(11):e143-e145. PMID: 31559417.
    Citations: 5     Fields:    Translation:Humans
  22. Vermeire S, Dreesen E, Papamichael K, Dubinsky MC. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring? Clin Gastroenterol Hepatol. 2020 05; 18(6):1291-1299. PMID: 31589978.
    Citations: 13     Fields:    Translation:Humans
  23. Fudman DI, Papamichael K, Roemi L, Rao V, Falchuk KR, Leffler DA, Feuerstein JD. Effect of Consent and Educational Adjuncts to Consent on Patient Perceptions About Colonoscopy. J Clin Gastroenterol. 2019 09; 53(8):e316-e321. PMID: 30001290.
    Citations:    Fields:    Translation:Humans
  24. Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2019 Aug 14; 13(8):976-981. PMID: 30689771.
    Citations: 19     Fields:    Translation:Humans
  25. Papamichael K, Papaioannou G, Cheifetz MA, Cheifetz AS. Bone of Contention: Helicobacter pylori and Osteoporosis-Is There an Association? Dig Dis Sci. 2019 10; 64(10):2736-2739. PMID: 31407131.
    Citations: 1     Fields:    Translation:HumansCells
  26. Papamichael K, Cheifetz AS. Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease? Gastroenterology. 2019 10; 157(4):922-924. PMID: 31400368.
    Citations: 1     Fields:    Translation:Humans
  27. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019 07; 35(4):302-310. PMID: 30973355.
    Citations: 4     Fields:    Translation:Humans
  28. Politis DS, Katsanos KH, Papamichael K, Saridi M, Albani E, Christodoulou DK. Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores? World J Gastrointest Endosc. 2019 Jun 16; 11(6):424-426. PMID: 31236195.
    Citations:    
  29. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 08; 15(8):837-848. PMID: 31180729.
    Citations: 12     Fields:    Translation:Humans
  30. Papamichael K, Cheifetz AS. Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD Therapy. Dig Dis Sci. 2019 06; 64(6):1397-1398. PMID: 30927210.
    Citations:    Fields:    Translation:Humans
  31. Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflamm Bowel Dis. 2019 05 04; 25(6):998-1005. PMID: 30590558.
    Citations: 1     Fields:    Translation:Humans
  32. Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 08; 17(9):1655-1668.e3. PMID: 30928454.
    Citations: 32     Fields:    Translation:Humans
  33. Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019; 10:2040622319838443. PMID: 30937157.
    Citations: 12     
  34. Papamichael K, Delitheos B, Mourouzis I, Pantos C, Tiligada E. L-Thyroxine induces thermotolerance in yeast. Cell Stress Chaperones. 2019 03; 24(2):469-473. PMID: 30737613.
    Citations:    Fields:    Translation:Animals
  35. Politis DS, Papamichael K, Katsanos KH, Koulouridis I, Mavromati D, Tsianos EV, Christodoulou DK. Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. Ann Gastroenterol. 2019 Mar-Apr; 32(2):168-173. PMID: 30837789.
    Citations: 1     
  36. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn's Disease. Inflamm Bowel Dis. 2018 09 15; 24(10):2266-2271. PMID: 29718327.
    Citations: 15     Fields:    Translation:Humans
  37. Danford CJ, Trivedi HD, Papamichael K, Tapper EB, Bonder A. Osteoporosis in primary biliary cholangitis. World J Gastroenterol. 2018 Aug 21; 24(31):3513-3520. PMID: 30131657.
    Citations: 3     Fields:    Translation:Humans
  38. Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018 11; 63(11):3067-3073. PMID: 30006816.
    Citations: 16     Fields:    Translation:Humans
  39. Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jun 28; 12(7):804-810. PMID: 29590345.
    Citations: 25     Fields:    Translation:Humans
  40. Papamichael K, Cheifetz AS. Letter: infliximab concentrations during induction therapy-one size does not fit all. Aliment Pharmacol Ther. 2018 05; 47(9):1334-1335. PMID: 29644743.
    Citations: 1     Fields:    Translation:Humans
  41. Papamichael K, Cheifetz AS, Osterman MT. Reply. Clin Gastroenterol Hepatol. 2018 04; 16(4):598-599. PMID: 29555231.
    Citations:    Fields:    Translation:Humans
  42. Clarke WT, Amin SS, Papamichael K, Feuerstein JD, Cheifetz AS. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018 06; 191:59-62. PMID: 29601854.
    Citations:    Fields:    Translation:HumansCells
  43. Katsanos KH, Papamichael K, Feuerstein JD, Christodoulou DK, Cheifetz AS. Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clin Immunol. 2019 09; 206:9-14. PMID: 29545207.
    Citations: 20     Fields:    Translation:Humans
  44. Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):465-466. PMID: 29462402.
    Citations:    Fields:    Translation:Humans
  45. Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202. PMID: 29432749.
    Citations: 7     Fields:    Translation:Humans
  46. Papamichael K, Cheifetz AS. Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 02; 47(3):436-437. PMID: 29314123.
    Citations:    Fields:    Translation:Humans
  47. Papamichael K, Vajravelu RK, Osterman MT, Cheifetz AS. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018 03; 63(3):761-767. PMID: 29340807.
    Citations: 8     Fields:    Translation:Humans
  48. Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018 Jan 05; 12(1):17-31. PMID: 28981623.
    Citations: 25     Fields:    Translation:HumansPHPublic Health
  49. Grossberg LB, Papamichael K, Feuerstein JD, Siegel CA, Ullman TA, Cheifetz AS. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 12 19; 24(1):191-197. PMID: 29272486.
    Citations: 13     Fields:    Translation:Humans
  50. Papamichael K, Rakowsky S, Rivera C, Cheifetz AS, Osterman MT. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018 02; 47(4):478-484. PMID: 29210094.
    Citations: 19     Fields:    Translation:Humans
  51. Papamichael K, Cheifetz AS. Response to Reinink. Am J Gastroenterol. 2017 12; 112(12):1893-1894. PMID: 29215625.
    Citations:    Fields:    
  52. Feuerstein JD, Papamichael K, Popejoy S, Nadelson A, Lewandowski JJ, Geissler K, Martinez-Vazquez M, Leffler DA, Ariyabuddhiphongs K, Thukral C, Cheifetz AS. Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. Dig Dis Sci. 2018 01; 63(1):36-45. PMID: 29147880.
    Citations: 2     Fields:    Translation:Humans
  53. Katsanos KH, Papamichael K, Christodoulou DK, Cheifetz AS. Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission? Dig Liver Dis. 2017 12; 49(12):1332-1333. PMID: 28964677.
    Citations:    Fields:    Translation:Humans
  54. Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. World J Gastroenterol. 2017 Sep 14; 23(34):6197-6200. PMID: 28974885.
    Citations: 3     Fields:    Translation:Humans
  55. Papamichael K, Vande Casteele N, Ferrante M, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. Inflamm Bowel Dis. 2017 09; 23(9):1510-1515. PMID: 28816757.
    Citations: 16     Fields:    Translation:Humans
  56. Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017 09; 23(9):1605-1613. PMID: 28590343.
    Citations: 6     Fields:    Translation:HumansCells
  57. Grossberg LB, Vodonos A, Papamichael K, Novack V, Sawhney M, Leffler DA. Predictors of post-colonoscopy emergency department use. Gastrointest Endosc. 2018 02; 87(2):517-525.e6. PMID: 28859952.
    Citations:    Fields:    Translation:Humans
  58. Detrez I, Van Stappen T, Martín Arranz MD, Papamichael K, Gils A. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Ther Drug Monit. 2017 08; 39(4):344-349. PMID: 28328760.
    Citations: 2     Fields:    Translation:HumansAnimals
  59. Papamichael K, Osterman MT, Cheifetz AS. Reply. Clin Gastroenterol Hepatol. 2017 10; 15(10):1638-1639. PMID: 28603051.
    Citations:    Fields:    Translation:Humans
  60. Papamichael K, Cheifetz AS. Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough? Aliment Pharmacol Ther. 2017 05; 45(9):1265-1266. PMID: 28370052.
    Citations:    Fields:    Translation:Humans
  61. Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1580-1588.e3. PMID: 28365486.
    Citations: 50     Fields:    Translation:Humans
  62. Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. Am J Gastroenterol. 2017 May; 112(5):673-676. PMID: 28220781.
    Citations: 18     Fields:    Translation:Humans
  63. Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, Ferrante M. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. Eur J Gastroenterol Hepatol. 2017 Jan; 29(1):84-90. PMID: 27603297.
    Citations: 2     Fields:    Translation:Humans
  64. Van Stappen T, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, Ferrante M, Vermeire S, Gils A. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. Clin Transl Gastroenterol. 2016 Dec 08; 7(12):e206. PMID: 27929524.
    Citations: 16     Fields:    
  65. Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. J Crohns Colitis. 2017 Jan; 11(1):53-59. PMID: 27402915.
    Citations: 26     Fields:    Translation:Humans
  66. Kopylov U, Katsanos KH, van der Woude CJ, Karmiris K, Hernandez V, Odes S, Papamichael K, Koutroubakis IE, Bojic D, Kaimakliotis I, Fiorino G, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris GJ, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. Eur J Gastroenterol Hepatol. 2016 Jul; 28(7):802-6. PMID: 26894634.
    Citations: 3     Fields:    Translation:Humans
  67. Miligkos M, Papamichael K, Vande Casteele N, Mantzaris GJ, Gils A, Levesque BG, Zintzaras E. Efficacy and Safety Profile of Anti-tumor Necrosis Factor-a Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons. Clin Ther. 2016 Jun; 38(6):1342-1358.e6. PMID: 27091732.
    Citations: 10     Fields:    Translation:Humans
  68. Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab. J Crohns Colitis. 2016 Sep; 10(9):1015-23. PMID: 27022161.
    Citations: 15     Fields:    Translation:Humans
  69. Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016 Oct; 7(4):289-300. PMID: 28839870.
    Citations: 20     
  70. Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf. 2016; 15(4):493-501. PMID: 26799429.
    Citations: 6     Fields:    Translation:Humans
  71. Papamichael K, Cheifetz AS. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2016 May; 10(5):507-9. PMID: 26874348.
    Citations: 3     Fields:    Translation:Humans
  72. Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):543-9. PMID: 26681486.
    Citations: 46     Fields:    Translation:Humans
  73. Papamichael K, Karatzas P, Mantzaris GJ. De-escalation of Infliximab Maintenance Therapy from 8- to 10-week Dosing Interval Based on Faecal Calprotectin in Patients with Crohn's Disease. J Crohns Colitis. 2016 Mar; 10(3):371-2. PMID: 26546496.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  74. Mantzaris GJ, Papamichael K. Author's reply to Performance of interferon-gamma release assay for tuberculosis screening in inflammatory bowel disease patients: disease activity as an influencing factor. Scand J Gastroenterol. 2016 Mar; 51(3):382. PMID: 26425891.
    Citations:    Fields:    Translation:Humans
  75. Mantzaris GJ, Viazis N, Polymeros D, Papamichael K, Bamias G, Koutroubakis IE. Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol. 2015 Oct-Dec; 28(4):417-25. PMID: 26424173.
    Citations: 2     
  76. Papamichael K, Karatzas P, Theodoropoulos I, Kyriakos N, Archavlis E, Mantzaris GJ. Simethicone adjunct to polyethylene glycol improves small bowel capsule endoscopy imaging in non-Crohn's disease patients. Ann Gastroenterol. 2015 Oct-Dec; 28(4):464-8. PMID: 26423317.
    Citations: 2     
  77. Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015 Nov; 42(10):1158-69. PMID: 26365281.
    Citations: 11     Fields:    Translation:Humans
  78. Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease. J Crohns Colitis. 2015 Dec; 9(12):1120-6. PMID: 26351386.
    Citations: 11     Fields:    Translation:Humans
  79. Potaris K, Kapetanakis E, Papamichail K, Midvighi E, Verveniotis A, Parissis F, Apostolou D, Tziortziotis V, Maimani S, Pouliara E, Vogiatzis G, Kakaris S, Konstantinou M. Major Lung Resections Using Manual Suturing Versus Staplers During Fiscal Crisis. Int Surg. 2015 Jul 27. PMID: 26215660.
    Citations:    Fields:    
  80. Mantzaris GJ, Tsironikos D, Tzanetakou X, Grispou E, Karatzas P, Kalogeropoulos I, Papamichael K. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scand J Gastroenterol. 2015; 50(12):1451-5. PMID: 26139305.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  81. Ferrante M, Papamichael K, Duricova D, D'Haens G, Vermeire S, Archavlis E, Rutgeerts P, Bortlik M, Mantzaris G, Van Assche G. Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence. J Crohns Colitis. 2015 Aug; 9(8):617-24. PMID: 25926532.
    Citations: 9     Fields:    Translation:Humans
  82. Papamichael K, Vermeire S. Withdrawal of anti-tumour necrosis factor a therapy in inflammatory bowel disease. World J Gastroenterol. 2015 Apr 28; 21(16):4773-8. PMID: 25944990.
    Citations: 9     Fields:    Translation:Humans
  83. Papamichael K, Karatzas P, Mantzaris GJ. Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease. J Crohns Colitis. 2015 Jul; 9(7):589-90. PMID: 25863276.
    Citations: 3     Fields:    Translation:Humans
  84. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. PMID: 25222660.
    Citations: 38     Fields:    Translation:Humans
  85. Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1103-10. PMID: 25478919.
    Citations: 17     Fields:    Translation:Humans
  86. Papamichael K, Konstantopoulos P, Mantzaris GJ. Helicobacter pylori infection and inflammatory bowel disease: is there a link? World J Gastroenterol. 2014 Jun 07; 20(21):6374-85. PMID: 24914359.
    Citations: 34     Fields:    Translation:HumansCells
  87. Kassi G, Papamichael K, Papaioannou G, Giagourta I, Thanou S, Triantaphyllopoulou M, Zapanti E, Papandroulaki F, Ktena V, Karga H. Cytokines and insulin resistance after zoledronic acid-induced acute phase response. Immunol Invest. 2014; 43(6):544-55. PMID: 24661204.
    Citations: 2     Fields:    Translation:Humans
  88. Makris M, Aggelides X, Chliva C, Katoulis A, Papamichael K, Tiligada E. High baseline blood histamine levels and lack of cross-reactivity in a patient with ranitidine-induced anaphylaxis. J Investig Allergol Clin Immunol. 2014; 24(5):361-3. PMID: 25345311.
    Citations:    Fields:    Translation:Humans
  89. Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S, Danese S, Fiorino G. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014 Feb; 46(2):135-9. PMID: 24246151.
    Citations: 15     Fields:    Translation:Humans
  90. Papamichael K, Karatzas P, Mantzaris GJ. Faecal calprotectin but not C-reactive protein (CRP) or Crohn's Disease Activity Index (CDAI) may predict post-operative endoscopic recurrence of Crohn's disease. J Crohns Colitis. 2013 Dec; 7(12):e700-1. PMID: 23953238.
    Citations: 6     Fields:    Translation:Humans
  91. Gazouli M, Anagnostopoulos AK, Papadopoulou A, Vaiopoulou A, Papamichael K, Mantzaris G, Theodoropoulos GE, Anagnou NP, Tsangaris GT. Serum protein profile of Crohn's disease treated with infliximab. J Crohns Colitis. 2013 Nov; 7(10):e461-70. PMID: 23562004.
    Citations: 15     Fields:    Translation:HumansCells
  92. Papamichael K, Delitheos B, Tiligada E. A subset of histamine receptor ligands improve thermotolerance of the yeast Saccharomyces cerevisiae. J Appl Microbiol. 2013 Feb; 114(2):492-501. PMID: 23121472.
    Citations: 2     Fields:    Translation:AnimalsCells
  93. Papamichael K, Mantzaris GJ. Reply to Dr. Yamamoto's letter. J Crohns Colitis. 2013 May; 7(4):e158. PMID: 23040450.
    Citations:    Fields:    Translation:Humans
  94. Papamichael K, Archavlis E, Lariou C, Tsigka A, Mantzaris GJ. Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship? Eur J Gastroenterol Hepatol. 2012 Jul; 24(7):857-9. PMID: 22475791.
    Citations: 1     Fields:    Translation:Humans
  95. Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis. 2012 Oct; 6(9):924-31. PMID: 22424843.
    Citations: 20     Fields:    Translation:HumansPHPublic Health
  96. Kyriakos N, Papamichael K, Archavlis E, Agalos G, Mantzaris GJ. Long term safety and efficacy of H1N1 vaccine in a single-center cohort of IBD patients treated with immunomodulators and/or anti-TNFa biologics. J Crohns Colitis. 2012 Mar; 6(2):264-5. PMID: 22325186.
    Citations:    Fields:    Translation:HumansCells
  97. Papamichael K, Gazouli M, Karakoidas C, Panayotou I, Roma-Giannikou E, Mantzaris GJ. Association of TNF and Fc?R???A gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Ann Gastroenterol. 2011; 24(1):35-40. PMID: 24714240.
    Citations: 8     
  98. Papaioannou G, Michelis FV, Papamichael K, Karga H, Tiligada E. Blood lymphocyte blastogenesis in patients with thyroid dysfunction: ex vivo response to mitogen activation and cyclosporin A. Inflamm Res. 2011 Mar; 60(3):265-70. PMID: 20972816.
    Citations:    Fields:    Translation:HumansCells
  99. Karga H, Giagourta I, Papaioannou G, Doumouchtsis K, Polymeris A, Thanou S, Papamichael K, Zerva C. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin. Metabolism. 2011 May; 60(5):604-8. PMID: 20667564.
    Citations: 3     Fields:    Translation:Humans
  100. Koutroubakis IE, Drygiannakis D, Tsirogianni A, Oustamanolakis P, Karmiris K, Papamichael K, Mantzaris GJ, Kouroumalis EA. Antiglycan antibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2011 Mar; 56(3):845-52. PMID: 20632100.
    Citations: 4     Fields:    Translation:Humans
  101. Papamichael K, Tsirogianni A, Papasteriades C, Mantzaris GJ. Low prevalence of antibodies to cyclic citrullinated peptide in patients with inflammatory bowel disease regardless of the presence of arthritis. Eur J Gastroenterol Hepatol. 2010 Jun; 22(6):705-9. PMID: 19525851.
    Citations: 6     Fields:    Translation:Humans
  102. Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab. Rev Med Chir Soc Med Nat Iasi. 2010 Jan-Mar; 114(1):85-90. PMID: 20509281.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  103. Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A, Karakoidas C, Koilakou S, Raptis N, Smyrnidis A, Agalos G, Karamanolis DG. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. Eur J Gastroenterol Hepatol. 2009 Sep; 21(9):1042-8. PMID: 20139856.
    Citations: 3     Fields:    Translation:Humans
  104. Delitheos B, Papamichael K, Tiligada E. Histamine modulates the cellular stress response in yeast. Amino Acids. 2010 Apr; 38(4):1219-26. PMID: 19653065.
    Citations: 1     Fields:    Translation:AnimalsCells
  105. Karga H, Papaioannou G, Polymeris A, Papamichael K, Karpouza A, Samouilidou E, Papaioannou P. The effects of recombinant human TSH on bone turnover in patients after thyroidectomy. J Bone Miner Metab. 2010; 28(1):35-41. PMID: 19548061.
    Citations: 6     Fields:    Translation:Humans
  106. Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. 2009 Jun 14; 15(22):2701-7. PMID: 19522019.
    Citations: 33     Fields:    Translation:HumansCells
  107. Michelis FV, Petrogiannopoulos CL, Papamichael KX, Kostakos ND, Kiagia EZ, Deliousis A, Zacharof AK. Lymphomatous pericardial effusion positive for Mycobacterium tuberculosis by PCR analysis. Int J Infect Dis. 2008 Sep; 12(5):564-5. PMID: 18406651.
    Citations:    Fields:    Translation:Humans
  108. Petrogiannopoulos C, Papamichael K, Karachalios G, Karachaliou I, Kostakos N, Barbati K, Zacharof A. Autoimmune cholangitis presented as fever of unknown origin. Chemotherapy. 2006; 52(6):282-4. PMID: 17008778.
    Citations:    Fields:    Translation:Humans
  109. Tiligada E, Papamichael K, Vovou I, Delitheos A. Circumvention of camptothecin-induced resistance during the adaptive cellular stress response. Anticancer Res. 2006 Jan-Feb; 26(1A):421-5. PMID: 16475727.
    Citations:    Fields:    Translation:Animals
  110. Papamichael K, Vovou I, Miligkos V, Stavrinidis E, Delitheos A, Tiligada E. Effect of the Hsp90 modulators on the heat-shock response in eukaryotic cells. Folia Microbiol (Praha). 2006; 51(1):33-7. PMID: 16821709.
    Citations: 1     Fields:    Translation:Animals
  111. Papamichail KN, French S. Decision support in nuclear emergencies. J Hazard Mater. 2000 Jan 07; 71(1-3):321-42. PMID: 10677668.
    Citations:    Fields:    Translation:Humans
  112. Miligkos V, Tiligada E, Papamichael K, Ypsilantis E, Delitheos A. Anticancer drugs as inducers of thermotolerance in yeast. Folia Microbiol (Praha). 2000; 45(4):339-42. PMID: 11347257.
    Citations: 2     Fields:    Translation:Animals
  113. Tiligada E, Miligkos V, Ypsilantis E, Papamichael K, Delitheos A. Molybdate induces thermotolerance in yeast. Lett Appl Microbiol. 1999 Aug; 29(2):77-80. PMID: 10499293.
    Citations: 4     Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Papamichail's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (317)
Explore
_
Co-Authors (25)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.